The U.S. Food and Drug Administration has put Chelmsford firmly on notice, issuing a formal warning to local mainstay ZOLL Medical after federal inspectors flagged what they called systemic problems in the company’s manufacturing and reporting systems. The findings touch defibrillators, ventilators and related accessories, raising uncomfortable questions for a plant that has long been one of the town’s biggest employers and a key supplier to hospitals and EMS crews.
The FDA posted its warning letter to ZOLL on April 30, following an inspection that ran from Feb. 27 through April 15, 2025. According to the agency, several ZOLL products were categorized as “adulterated” or “misbranded.” Devices named in the letter include X Series and X Series Advanced AEDs, the 731 Series MRI-compatible ventilators, OneStep electrodes and Accuvent sensors.
What inspectors flagged
Federal reviewers and industry reporting describe a pattern of quality and reporting shortfalls. The letter criticizes ZOLL’s corrective-and-preventive-action procedures as ineffective, says supplier risks were mischaracterized, and notes the company failed to submit a timely medical-device report after a ventilator incident. According to MassDevice, the FDA also took aim at ZOLL’s RescueNet Live software, saying it appears to analyze monitoring data and generate secondary alarms, which would make it a device that requires premarket approval.
Local stakes for Chelmsford
For Chelmsford, this is not some distant regulatory spat. ZOLL’s campus is a major local employer, with about 1,085 workers in town, according to the Boston Business Journal. Town financial documents and economic profiles also list ZOLL among Chelmsford’s largest employers, historically at roughly 1,077 jobs, per town records.
Company context and recent moves
Even as it faces the warning letter, ZOLL has been busy on the business front. Earlier this year the company announced FDA approval for its Zenix monitor/defibrillator and named Eric Knudsen as CEO. Press materials from ZOLL highlight the Zenix rollout and leadership change, underscoring that the firm remains an active player in EMS and hospital markets even as it works through federal compliance issues.
What comes next
The clock is already ticking. The FDA has given ZOLL fifteen business days to notify the agency in writing about the specific steps it has taken to correct the violations, along with documentation or a timetable for any remaining fixes. The agency warned that failure to adequately address the problems could trigger seizure, injunction or civil money penalties and could block future approvals or Certificates to Foreign Governments, turning ZOLL’s written response into a high-stakes deadline for customers, contracts and the hometown workforce alike.
